Contributions
Abstract: EP1298
Type: ePoster
Abstract Category: Clinical aspects of MS - 2 MS Variants
Background: Neuromyelitis optica spectrum disorder (NMOSD) was suggested to have a more severe course in low and middle income countries, particularly among populations from North Africa.
Objectives: To describe the clinical course and prognosis of NMOSD in a Moroccan NMOSD population.
Patients and methods: A retrospective monocenter study was conducted. Patients from January 1999 to December 2015 fulfilling the 2015 International Consensus Criteria for NMOSD were included.
Results: Sixty four patients were included. Mean age at onset was 35,7 ± 10,7 years, and the sex ratio was 1/3,56. Non transverse myelitis (NTM) was the initial clinical event in 29,4%, 17,2% presented with a Devic's syndrome and 15,6% with intractable hiccups nausea and vomiting syndrome. Half of patients had more NTM attacks than transverse myelitis. Brain lesions were found in 71,2%. Twenty four percents had associated autoimmune diseases. Approximately half of patients reached an EDSS score of 6 after a median disease duration of 5,7 years, and 18,8% had an EDSS less than 1,5 on follow up. Median progression index was 0,78 and median multiple sclerosis severity score was 8,64. Disease age of onset (HR 1,51 for each decade; 95% CI 1,08-2,11), myelitis (HR 2,72; 95% CI 1,05-7,05) or multifocal first clinical event (HR 3,34; 95% CI 1,20 - 9,35), ratio of NTM (HR 0,04; 95% CI 0,01-0,30) and being under disease-modifying therapy (HR 0,31;
95% CI 0,15-0,64) were the only factors associated with progression to an EDSS score of 6.
Conclusion: We could not found any study using the new criteria for NMOSD to study their prognosis. Hence, comparisons are difficult to make and conclusions difficult to draw. However, our patients seem to have a worse outcome, even with broad criteria that include subtypes of patients with a better prognosis.
Disclosure:
A. Bennis: nothing to disclose
H. El Otmani: nothing to disclose
F. Dany: nothing to disclose
B. El Moutawakil: nothing to disclose
M.A. Rafai: nothing to disclose
I. Slassi: nothing to disclose
Abstract: EP1298
Type: ePoster
Abstract Category: Clinical aspects of MS - 2 MS Variants
Background: Neuromyelitis optica spectrum disorder (NMOSD) was suggested to have a more severe course in low and middle income countries, particularly among populations from North Africa.
Objectives: To describe the clinical course and prognosis of NMOSD in a Moroccan NMOSD population.
Patients and methods: A retrospective monocenter study was conducted. Patients from January 1999 to December 2015 fulfilling the 2015 International Consensus Criteria for NMOSD were included.
Results: Sixty four patients were included. Mean age at onset was 35,7 ± 10,7 years, and the sex ratio was 1/3,56. Non transverse myelitis (NTM) was the initial clinical event in 29,4%, 17,2% presented with a Devic's syndrome and 15,6% with intractable hiccups nausea and vomiting syndrome. Half of patients had more NTM attacks than transverse myelitis. Brain lesions were found in 71,2%. Twenty four percents had associated autoimmune diseases. Approximately half of patients reached an EDSS score of 6 after a median disease duration of 5,7 years, and 18,8% had an EDSS less than 1,5 on follow up. Median progression index was 0,78 and median multiple sclerosis severity score was 8,64. Disease age of onset (HR 1,51 for each decade; 95% CI 1,08-2,11), myelitis (HR 2,72; 95% CI 1,05-7,05) or multifocal first clinical event (HR 3,34; 95% CI 1,20 - 9,35), ratio of NTM (HR 0,04; 95% CI 0,01-0,30) and being under disease-modifying therapy (HR 0,31;
95% CI 0,15-0,64) were the only factors associated with progression to an EDSS score of 6.
Conclusion: We could not found any study using the new criteria for NMOSD to study their prognosis. Hence, comparisons are difficult to make and conclusions difficult to draw. However, our patients seem to have a worse outcome, even with broad criteria that include subtypes of patients with a better prognosis.
Disclosure:
A. Bennis: nothing to disclose
H. El Otmani: nothing to disclose
F. Dany: nothing to disclose
B. El Moutawakil: nothing to disclose
M.A. Rafai: nothing to disclose
I. Slassi: nothing to disclose